Last reviewed · How we verify
PRULIFLOXACIN — Competitive Intelligence Brief
phase 3
prulifloxacin
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
PRULIFLOXACIN (PRULIFLOXACIN). Prulifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PRULIFLOXACIN TARGET | PRULIFLOXACIN | phase 3 | prulifloxacin |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (prulifloxacin class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PRULIFLOXACIN CI watch — RSS
- PRULIFLOXACIN CI watch — Atom
- PRULIFLOXACIN CI watch — JSON
- PRULIFLOXACIN alone — RSS
- Whole prulifloxacin class — RSS
Cite this brief
Drug Landscape (2026). PRULIFLOXACIN — Competitive Intelligence Brief. https://druglandscape.com/ci/prulifloxacin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing